Feasibility of Semaglutide in Advanced Lung Disease

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.The main question[s] it aims to answer are:Are patients with advanced lung disease able to tolerate semaglutide therapy?Are we able to titrate semaglutide therapy to a target weight?Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

Inclusion Criteria:Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertensionAge > 18BMI > 30 kg/m2Requires supplemental oxygen on exertionStable treatment regimen X 90 daysUse of disease-modifying therapyExclusion Criteria:DiabetesPregnant or BreastfeedingRecent weight lossRecent or chronic GI complaintsHistory of gastroparesisHistory of sclerodermaHospitalized at time of evaluationUse of weight loss medication in last 90 daysPersonal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)Uncontrolled thyroid diseaseHistory of acute/chronic pancreatitisPrior suicide attemptSuicidal ideation in last 90 daysPresence of a pacemaker or defibrillator